Patheon acquires Roche’s manufacturing facility in South Carolina, US

Drug development and delivery solutions provider Patheon has completed the acquisition of a manufacturing facility from Roche in Florence, South Carolina, US.

The company started integrating the site into its network, which will add a 300,000ft² facility with manufacturing capacity for active pharmaceutical ingredient (API) ranging from development to manufacturing services.

The addition of this site will enable Patheon to expand its capacity for manufacturing highly potent compounds and also supports solid state chemistry, micronisation and future commercial spray drying.

Patheon drug substance services president Lukas Utiger said: "We are extremely pleased to add this facility to the Patheon network and the talented professionals that will support a wide range of drug substance services.

"Patheon has extensive experience and success integrating new sites into our global network and quickly leveraging the capabilities for the benefit of our clients."

The pharmaceutical manufacturing facility’s production space features reactors ranging from 50l to 11,000l capable of producing multiple products simultaneously.

The site additionally provides flexible operations, allowing the company to adapt to new production needs quickly.

Serving as Patheon’s US API operation for commercial scale and mid-scale API production, the site will also improve the company’s pharma presence in the US market.

The latest acquisition is the company’s sixth in the last five years and supports its plans to create an integrated provider of pharma development and manufacturing services.